Ocuphire Pharma Inc - Company Profile
Powered by 
All the data and insights you need on Ocuphire Pharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Ocuphire Pharma Inc Strategy Report
- Understand Ocuphire Pharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ocuphire Pharma Inc (Ocuphire) is a clinical-stage biopharmaceutical company that develops novel therapies for retinal and refractive eye disorders. The company's product candidates include APX3330, a small-molecule inhibitor of Ref-1, and Phentolamine Ophthalmic Solution 0.75% (PS), an eye drop formulation of phentolamine mesylate. Its APX3330 is being developed for the treatment of diabetic retinopathy and diabetic macular edema. The company markets its products under the brand RYZUMVI. Ocuphire's products are aimed at addressing the unmet needs of patients with various eye disorders, including those suffering from diabetic retinopathy, a condition that affects millions of diabetics worldwide. The company collaborates with Viatris, Inc. for the development and commercialization of its refractive product candidate. Ocuphire is headquartered in Farmington Hills, Michigan, the US.
Headquarters
United States of America
Address
37000 Grand River Ave., Suite 120, Farmington Hills, Michigan, 48335
Website
www.ocuphire.com
Telephone
1 248 6819815
No of Employees
14
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OCUP (NASD)
Revenue (2022)
$19.0M
-52.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-155.8%
(2022 vs 2021)
Market Cap*
$40.7M
Net Profit Margin (2022)
XYZ
-216.8%
(2022 vs 2021)
* As of and is in US$
Ocuphire Pharma Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | RYZUMVI |
| APX3330: Diabetic Retinopathy | |
| APX2009: Retina | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Others | In January, the company received agreement from the US Food and Drug Administration for the clinical trial protocol and planned statistical analysis of the LYNX-2 Phase 3 trial for the treatment of decreased visual acuity under dim (mesopic) light conditions. |
| 2023 | New Product Approvals | In February, the company received approval from U.S. Food and Drug Administration for it's Nyxol (phentolamine ophthalmic solution 0.75%) for the treatment of pharmacologically-induced mydriasis (RM). |
| 2022 | Others | In April, the company announced positive results in the MIRA-4 pediatric safety trial investigating its product candidate Nyxol for the reversal of pharmacologically-induced mydriasis (dilation of pupil). |
Competitor Comparison
| Key Parameters | Ocuphire Pharma Inc | Merck & Co Inc | Cyclacel Pharmaceuticals Inc | Eyenovia Inc | Aciont Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Farmington Hills | Kenilworth | Berkeley Heights | New York | Salt Lake |
| State/Province | Michigan | New Jersey | New Jersey | New York | Utah |
| No. of Employees | 14 | 72,000 | 12 | 57 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Cam Gallagher | Chairman | Executive Board | 2020 | 53 |
| George Magrath | Director; Chief Executive Officer | Executive Board | 2023 | - |
| Nirav Jhaveri | Chief Financial Officer | Senior Management | - | - |
| Joseph Schachle | Chief Operating Officer | Senior Management | 2023 | - |
| Amy Rabourn | Senior Vice President - Finance | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer